UNH
HealthcareUnitedHealth Group
Price Chart
Market Data
Financials
XBRL · SEC EDGAR2022–2025(4yr)| Metric | FY 2022 | FY 2023 | FY 2024 | FY 2025Latest | YoY |
|---|---|---|---|---|---|
| Revenue | $324.2B | $371.6B | $400.3B | $447.6B | +11.8% |
| Gross Profit | $290.5B | $332.9B | $353.6B | $396.9B | +12.3% |
| Gross Margin | 89.6% | 89.6% | 88.3% | 88.7% | +0.3pp |
| Operating Income | $28.4B | $32.4B | $32.3B | $19.0B | -41.3% |
| Operating Margin | 8.8% | 8.7% | 8.1% | 4.2% | -3.8pp |
| Net Income | $20.1B | $22.4B | $14.4B | $12.1B | -16.3% |
| Net Margin | 6.2% | 6.0% | 3.6% | 2.7% | -0.9pp |
| Free Cash Flow | $23.4B | $25.7B | $20.7B | $16.1B | -22.4% |
| FCF Margin | 7.2% | 6.9% | 5.2% | 3.6% | -1.6pp |
| EPS (Diluted) | $21.18 | $23.86 | $15.51 | $13.23 | -14.7% |
1. THE BIG PICTURE
UnitedHealth Group is attempting to prove that its massive, integrated model—combining insurance (UnitedHealthcare) with healthcare delivery and data (Optum)—can withstand a period of intense operational volatility. While UnitedHealth Group remains a dominant revenue engine, it is currently in a defensive "re-baselining" phase where it must realign its pricing to catch up with a sharp spike in medical utilization that has temporarily derailed its earnings power.
2. WHERE THE RISKS HIT HARDEST
The core strength of UnitedHealth Group’s integrated model is threatened by medical cost estimation because risk-based products account for nearly 80% of consolidated revenues. UnitedHealth Group’s inability to recover cost increases through higher premiums during fixed contract periods was vividly illustrated in the fourth quarter of 2025, when earnings from operations plummeted to $0.4 billion from $7.8 billion a year earlier (8-K). Furthermore, UnitedHealth Group’s reliance on data and analytics as a competitive differentiator is directly undermined by cybersecurity incidents like the 2024 Change Healthcare attack, which creates material liabilities and threatens the operational continuity of its information-heavy Optum Insight segment.
3. WHAT THE NUMBERS SAY TOGETHER
While UnitedHealth Group maintains a massive revenue lead over peers at $435.2 billion, its recent results reveal a business struggling to convert that scale into profit. Revenue grew 11.8% over the last twelve months, yet operating margins compressed by 3.9 percentage points (XBRL). The fourth quarter of 2025 showed a stark divergence: UnitedHealthcare revenue rose to $87.1 billion, but its operating earnings fell from $3.0 billion to just $0.3 billion (8-K). This suggests that the current growth is being driven by higher enrollment and volume that UnitedHealth Group has not yet successfully priced for profitability. Despite these headwinds, market sentiment remains stable, with short interest at a low 1.5% of the float.
4. IS IT WORTH IT AT THIS PRICE?
At 14.2x Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, UnitedHealth Group trades at a modest 12% discount to the peer median of 16.2x. This discount is justified by the significant earnings volatility seen in late 2025 and the "re-baselining" required to address higher medical trends. According to the provided CAPM analysis, the market is currently pricing in a long-term growth rate of approximately 0.5%. This appears conservative given UnitedHealth Group’s 11.8% revenue growth and its 2026 guidance for revenue exceeding $439 billion. However, if growth were to stall entirely, the justified multiple would likely fall toward the 16.4x range implied by current costs of equity. The primary factor that could force investors to pay less is continued pressure on Medicare Advantage funding or a failure to stabilize the medical care ratio, which management has targeted at roughly 88.8% for 2026 (8-K).
5. WHAT WOULD CHANGE THIS VIEW?
- Constructive if the 2026 Medical Care Ratio stabilizes within the projected 88.8% range, proving that management’s "pricing discipline" has successfully accounted for higher medical trends.
- Cautious if Optum’s operating earnings do not rebound from the $0.1 billion reported in Q4 2025, as this would suggest structural rather than temporary issues in the high-margin service and technology segments (8-K).
6. BOTTOM LINE
Structural Advantage: A massive, closed-loop ecosystem that uses proprietary data and AI to manage healthcare costs across both a dominant insurance provider and a nationwide clinical service network.
Bottom Line: UnitedHealth Group is a high-quality compounder currently facing a rare earnings reset; the stock is attractively valued for patient investors if management can execute its 2026 margin recovery plan.
1. Top 5 Material Risks
- Medical Cost Estimation: The profitability of risk-based products—representing nearly 80% of consolidated revenues—depends on the ability to predict and price medical costs. Small variances in utilization rates or medical cost inflation can lead to significant changes in financial results, as cost increases typically cannot be recovered through higher premiums during a fixed contract period.
- Information Systems and Data Integrity: UnitedHealth Group depends on the integrity and availability of its data and information systems. Failure to maintain these systems, or the occurrence of cyberattacks, can lead to service failures, loss of customers, regulatory penalties, and increased operating expenses.
- Cybersecurity and Privacy: UnitedHealth Group is a frequent target of cyberattacks, including the 2024 Change Healthcare incident. Such events can result in the misappropriation of protected health information, operational shutdowns, and significant liability, with costs to remediate these threats often being material.
- Provider Relationships: The business relies on its ability to contract with physicians, hospitals, and other providers at competitive prices. Failure to maintain these relationships, or the emergence of competing Accountable Care Organizations (ACOs), can diminish bargaining power and increase medical costs.
- Market Competition: UnitedHealth Group faces significant competition in all markets. Failure to innovate, deliver value-based care models, or maintain market share—particularly if UnitedHealth Group loses accounts with more profitable products while retaining those with less profitable ones—could materially affect results of operations.
2. Company-Specific Risks
- Value-Based Care Integration: Optum Health’s fully accountable value-based arrangements require the successful integration of care delivery models; failure to provide higher-quality outcomes at lower costs could negatively impact financial positions.
- Acquisition Integration: UnitedHealth Group frequently engages in acquisitions, which present risks such as information technology vulnerabilities and different litigation risk profiles that may be more acute than those managed historically.
- Regulatory Capital Requirements: As a holding company, UnitedHealth Group depends on dividends from regulated subsidiaries. If these subsidiaries are required to maintain higher capital levels due to increased medical cost ratios, UnitedHealth Group’s ability to reinvest, service debt, or return capital to shareholders is constrained.
- Investment Portfolio Volatility: The substantial majority of UnitedHealth Group’s investments are in debt securities. Fluctuations in interest rates or defaults by issuers of corporate and municipal bonds could reduce investment income and require write-downs of investment values.
3. Regulatory/Legal Risks
- Government Program Funding: A significant portion of revenue is derived from Medicare Advantage, Medicare Part D, and Medicaid. Reductions in government funding, changes in allocation methodologies, or the termination of government contracts can materially affect results.
- Risk Adjustment Data Validation (RADV) Audits: CMS and the HHS Office of Inspector General perform RADV audits to validate coding practices. These audits have resulted in, and could continue to result in, retrospective payment adjustments, fines, and corrective action plans.
- Pharmacy Benefit Management (PBM) Regulation: Optum Rx is subject to federal and state laws governing relationships with pharmaceutical manufacturers and pharmacies. Investigations into PBM practices could lead to civil penalties, corporate integrity agreements, or fundamental changes to the PBM business model.
- ERISA Fiduciary Obligations: Pharmacy care services businesses provide services to ERISA-covered plans. If courts determine that fiduciary obligations apply to these services, UnitedHealth Group could face claims for breaches of fiduciary duty or prohibited transactions.
4. Financial Impact Map
- Medical Cost Estimation Errors → Medical Costs → Nearly 80% of consolidated revenues are derived from risk-based products where medical cost estimates involve extensive judgment.
- Cybersecurity Incidents → Operating Costs → Costs to eliminate threats and remediate incidents, such as the 2024 Change Healthcare cyberattack, are material and impact operating expenses.
- Medicare Advantage Funding Reductions → Premium Revenues → Funding pressures and benchmark reductions directly impact the revenue generated from Medicare Advantage programs.
- Goodwill Impairment → Goodwill → As of December 31, 2025, goodwill and other intangible assets totaled $131 billion, or 42% of total consolidated assets; impairment charges would directly reduce earnings.
- Investment Portfolio Defaults → Investment and Other Income → Defaults by issuers of corporate and municipal bonds would reduce investment income and require write-downs of investment values.
Recent Filings
| Form | Filed | Period |
|---|---|---|
| 10-K | Mar 2026 | Dec 2025 |
| 8-K | Jan 2026 | — |
| 10-Q | Oct 2025 | Sep 2025 |
| 14A | Apr 2025 | — |
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
UnitedHealth to remove prior authorization requirements for healthcare services starting in 2026
- ▸Prior authorization requirements to be removed for majority of services by 2026
- ▸Policy change aims to reduce administrative complexity for providers and patients
- ▸Shift expected to impact medical cost utilization and care management trends
- ▸UNH shares currently trading at $363.87, 6% below analyst consensus target
- ▸Company maintains 27.4x P/E ratio with high debt levels flagged as risk
Goldman Sachs Adds UnitedHealth to Conviction List, Maintains $435 Price Target
- ▸Goldman Sachs added UNH to U.S. Conviction List on May 1
- ▸Medicare Advantage underwriting cycle expected to be nearing bottom
- ▸Raymond James raised price target to $370 from $330 on April 21
- ▸Q1 adjusted EBIT beat estimates by $790M
- ▸Q1 core underlying earnings beat estimates by $1.19B
UnitedHealth Group AI Investment of $1.6B Targeted to Rebuild Optum Health Margins
- ▸Planned $1.5B–$1.6B AI investment for 2026
- ▸Avery generative AI platform to automate claims and reduce administrative costs
- ▸Raymond James upgraded stock to Outperform citing margin improvement potential
- ▸Projected 2028 revenue of $501.1B with $20.0B in earnings
- ▸Medicare cost pressures and regulatory scrutiny remain primary risk factors
UnitedHealth Q4 revenue $113.2B +12.3% YoY, shares down 22.3% post-earnings
- ▸UnitedHealth Q4 revenue $113.2B, up 12.3% YoY, meeting analyst expectations
- ▸UnitedHealth full-year revenue guidance missed analyst expectations significantly
- ▸UnitedHealth shares down 22.3% since earnings report, trading at $273.40
- ▸Clover Health Q4 revenue $487.7M, up 44.7% YoY, beating estimates by 4.4%
- ▸Health insurance sector stocks down 13.2% on average since latest earnings results
UnitedHealth upgraded to Outperform at Raymond James, $330 price target set
- ▸Raymond James upgraded UNH to Outperform from Market Perform
- ▸Analyst set $330 price target
- ▸Projected 2027-2028 EPS to exceed consensus by 7.5%–8%
- ▸AI initiatives expected to reduce operating costs and improve Optum Health margins
- ▸Stock currently trading at discount to historical 20x earnings valuation
Raymond James upgrades UnitedHealth to Outperform, cites AI-driven margin expansion potential
- ▸Raymond James upgrades UNH to Outperform from Market Perform
- ▸2027 EPS estimate raised to $21.33, 7.5% above consensus
- ▸2028 EPS estimate raised to $25.64, 8% above consensus
- ▸Optum Health EBIT projected to grow to $3.1B by 2028
- ▸AI initiatives expected to drive $1B in annual G&A savings
Raymond James upgrades UnitedHealth to Outperform, sets $330 price target
- ▸Raymond James upgrades UNH to Outperform from Market Perform
- ▸2026 operating earnings guidance exceeds $24B with 5.5% margin
- ▸Optum Health 2026 operating earnings growth projected at 9%
- ▸2026 adjusted EPS guidance set above $17.75
- ▸Medical care ratio expected to improve to 89% in 2026
UnitedHealth Launches Avery AI Companion to Automate Member Benefits and Claims Navigation
- ▸Avery AI companion launched for benefits navigation, scheduling, and claims status
- ▸Currently available to 6.5 million employer-sponsored and 160,000 Medicare Advantage members
- ▸Projected reach of 20.5 million total members by year-end 2026
- ▸90% of AI interactions require no human advocate assistance
- ▸Expected to improve operating leverage and consumer retention through administrative automation
UnitedHealth Launches Generative AI Assistant 'Avery' to Support 20.5 Million Members
- ▸Launched 'Avery' generative AI assistant for member navigation and support
- ▸Aims to automate 90% of member interactions without human intervention
- ▸Supports $1.6 billion total AI investment pipeline
- ▸Targeting rollout to approximately 20.5 million members
- ▸Tool integrates coverage details, claims tracking, and cost estimates
UnitedHealth expands doula support program nationally to 7.2 million members by 2027
- ▸National expansion of doula support program for eligible employer health plans
- ▸Program aims to improve maternal and infant health outcomes
- ▸Phased rollout currently underway across the United States
- ▸Potential access for 7.2 million members by January 1, 2027
- ▸Approximately 220,000 annual deliveries across employer-sponsored plans